feedback

Course Director

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Brigham and Women’s Hospital Heart & Vascular Center
Harvard Medical School
Boston, Massachusetts, USA

Faculty

Michael H. Davidson
Michael H. Davidson, MD, FACC, FNLA

The University of Chicago Pritzker School of Medicine
Chicago, Illinois, USA

Marc S. Sabatine
Marc S. Sabatine, MD, MPH

Brigham and Women's Hospital
Harvard Medical School
Boston, Massachusetts, USA

Accredited by

Oakstone Publishing, LLC

View Activity Materials

Activity Details

Credit Types:CME
Credit Amount:0.50 Credits
Release Date:2016-May-24
Expiration Date:2017-May-23
Estimated Time for Completion:30 minutes
Registration Required:No
Cost:Free of charge

Funding Disclosure

This activity is supported by an educational grant from Amgen, Inc.

Activity Description & Educational Objectives

In this activity, experts in cardiovascular medicine discuss the management of cardiovascular risk amongst patients with dyslipidaemia, particularly those who are unable to tolerate statin therapy.

Upon completion of this activity, participants should be better able to:

  • Define and describe statin intolerance in patients with lipid-related cardiovascular risk based on current evidence and guidelines
  • Evaluate the latest clinical data on managing lipid-related risk in patients with statin intolerance as well as other barriers to achieving target lipid levels
  • Develop individualised lipid-lowering treatment plans for patients with statin intolerance and other patients with persistent lipid-related cardiovascular risk

Target Audience

This activity has been designed to meet the educational needs of cardiologists, lipidologists, endocrinologists, and other clinicians involved in the management of lipid-related cardiovascular risk.

Faculty & Disclosure / Conflict of Interest Policy

Oakstone Publishing, LLC has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, medical reviewers, and editorial staff disclose no relevant financial relationships with commercial interests.

Course Director and Moderator

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular Programs,
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
Boston, Massachusetts, USA

Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, has a financial interest/relationship or affiliation in the form of:

Grant/Research Support from Amarin Corporation Plc; AstraZeneca Plc; Bristol-Myers Squibb; Eisai Company Limited; Ethicon Inc; Forest Laboratories LLC; Ischemix; Medtronic; Pfizer; Roche Pharma; Sanofi Aventis; and The Medicines Company

Interviewees

Michael H. Davidson, MD, FACC, FNLA
Professor, Director of the Lipid Clinic
The University of Chicago Pritzker School of Medicine
Chicago, Illinois, USA

Michael H. Davidson, MD, FACC, FNLA, has a financial interest/relationship or affiliation in the form of:

Consultant for Amgen, Inc; Regeneron Pharmaceuticals, Inc; and Sanofi
Speakers Bureau participant with Amgen, Inc; Regeneron Pharmaceuticals, Inc; and Sanofi
Honoraria from Amgen, Inc; Regeneron Pharmaceuticals, Inc; and Sanofi
Advisory Board for Amgen, Inc; Regeneron Pharmaceuticals, Inc; and Sanofi

Marc S. Sabatine, MD, MPH
Chairman, TIMI Study Group
Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine
Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School
Boston, Massachusetts, USA

Marc S. Sabatine, MD, MPH, has a financial interest/relationship or affiliation in the form of:

Consultant for Alnylam Pharmaceuticals; AstraZeneca; CVS Caremark; and Merck
Grant/Research Support from Abbott Laboratories; Amgen Inc.; AstraZeneca; Critical Diagnostics; Daiichi-Sankyo; Eisai Co., Ltd; Gilead; GlaxoSmithKline; Intarcia Therapeutics, Inc.; Merck; Novartis Pharmaceuticals; Poxel; Roche Diagnostics; Sanofi-Aventis; and Takeda Pharmaceuticals U.S.A., Inc.

Medical Director

Annette Wiggins
PeerVoice

Annette Wiggins has no financial interests/relationships or affiliations in relation to this activity.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labelled for use in certain jurisdictions. Faculty members have been advised to disclose to the audience any reference to an unlabelled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our materials. No responsibility is taken for errors or omissions in our materials.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing, LLC and PeerVoice. Oakstone Publishing, LLC is accredited by the ACCME to provide continuing medical education for physicians.

Oakstone Publishing, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

This CME activity is jointly provided by Oakstone Publishing, LLC and PeerVoice.

Requirements for Successful Completion

To receive credit, participants must complete the activity, the post-test, and the evaluation form prior to the expiration date noted below. There are no pre-requisites and there is no fee to participate in this activity or to receive credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form. Consult your professional licensing board for information about your eligibility to claim credit for participation in this educational activity. A minimum performance level of 70% is needed.

Media: Internet
Release and Expiration Dates: May 24, 2016 - May 23, 2017
Time to Complete: 30 minutes

Disclaimer

The participants of this educational activity have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.